i
Detection of Minimal Residual Disease in B Lymphoblastic Leukemia Using viSNE
-
2015 Sep-Oct
Source: Cytometry B Clin Cytom. 88(5):294-304.
[PDF-1.46 MB]
Details:
-
Alternative Title:Cytometry B Clin Cytom
-
Personal Author:
-
Description:Background Minimal residual disease (MRD) following treatment is a robust prognostic marker in B lymphoblastic leukemia. However, the detection of MRD by flow cytometric immunophenotyping is technically challenging, and an automated method to detect MRD is therefore desirable. viSNE, a recently developed computational tool based on the t-Distributed Stochastic Neighbor Embedding (t-SNE) algorithm, has been shown to be capable of detecting synthetic “MRD-like” populations of leukemic cells created in vitro, but whether viSNE can facilitate the immunophenotypic detection of MRD in clinical samples has not been evaluated. Methods We applied viSNE retrospectively to 8-color flow cytometric immunophenotyping data from normal bone marrow samples, and samples from B lymphoblastic leukemia patients with or without suspected MRD on the basis of conventional manual gating. Results In each of 14 bone marrow specimens containing MRD or suspected MRD, viSNE identified a putative MRD population; an abnormal composite immunophenotype was confirmed for the putative MRD in each case. MRD populations were not identified by viSNE in control bone marrow samples from patients with increased normal B-cell precursors, or in post-treatment samples from B lymphoblastic leukemia patients who did not have detectable MRD by manual gating. Conclusion viSNE shows promise as an automated method to facilitate immunophenotypic MRD detection in patients treated for B lymphoblastic leukemia.
-
Subject:
-
Pubmed ID:25974871
-
Pubmed Central ID:PMC5981136
-
Document Type:
-
Funding:
-
Collection(s):
-
Main Document Checksum:
-
File Type:
Supporting Files
-
jpeg 
gif 
jpeg 
gif 
jpeg 
gif 
jpeg 
xls 
docx 
xml 
gif 
jpeg 
gif 
jpeg 
gif
More +
Email
CDC-INFO
